Search

everythinglearnresearchcommunity

for

Search:↓

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.

Antioxidants can block the cancer-fighting effects of doxorubicin.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

A new compound shows promise as a topical treatment for hair loss.

Removing the ovarian tumor improved the woman's hormonal symptoms.

β-interferon injections for melanoma can cause excessive hair growth at the injection sites.

Nano-Pulse Stimulation™ Therapy is more effective and less damaging than cryoablation for treating melanoma tumors in mice.

The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.

2% Minoxidil does not prevent hair loss during chemotherapy.

Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.

Mononuclear cells may protect against certain chemotherapy-induced hair loss.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Surgery removed ovarian tumors, normalizing testosterone and improving symptoms.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Antihepcidin antibodies may treat inflammation-induced anemia by improving iron metabolism.

Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

New cytokine-targeted therapies show promise for treating alopecia areata.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.